The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure.
Partial fatty acid oxidation inhibitors have raised great interest since they are expected to counteract a dysregulated gene expression of hypertrophied cardiocytes. Some of these compounds have been developed for treating non-insulin-dependent diabetes mellitus and stable angina pectoris. A shift from fatty acid oxidation to glucose oxidation leads to a reduced gluconeogenesis and improved economy of cardiac work. An increased glucose oxidation can be achieved with the following enzyme inhibitors: etomoxir, oxfenicine, methyl palmoxirate, S-15176, metoprolol, amiodarone, perhexiline (carnitine palmitoyltransferase-1); aminocarnitine, perhexiline (carnitine palmitoyltransferase-2); hydrazonopropionic acid (carnitine-acylcarnitine translocase); MET-88 (gamma-butyrobetaine hydroxylase); 4-bromocrotonic acid, trimetazidine, possibly ranolazine (thiolases); hypoglycin (butyryl-CoA dehydrogenase); dichloroacetate (pyruvate dehydrogenase kinase). CLINICAL TRIALS with trimetazidine and ranolazine showed that this shift in substrate oxidation has an antianginal action. Etomoxir and MET-88 improved the function of overloaded hearts by increasing the density of the Ca(2+) pump of sarcoplasmic reticulum (SERCA2). The promoters of SERCA2 and alpha-myosin heavy-chain exhibit sequences which are expected to respond to transcription factors responsive to glucose metabolites and/or peroxisome proliferator-responsive element (PPAR) agonists. Further progress in elucidating novel compounds which upregulate SERCA2 expression is closely linked to the characterization of regulatory sequences of the SERCA2 promoter.
Rupp
Heinz
H
Molecular Cardiology Laboratory, Department of Internal Medicine and Cardiology, University of Marburg, Germany. Rupp@mailer.uni-marburg.de
Zarain-Herzberg
Angel
A
Maisch
Bernhard
B
D000083:Acetanilides; D000787:Angina Pectoris / Q000188:drug therapy* / Q000378:metabolism*; D000818:Animals; D002118:Calcium / Q000378:metabolism; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D004852:Epoxy Compounds / Q000627:therapeutic use*; D005227:Fatty Acids / Q000378:metabolism*; D015870:Gene Expression; D005947:Glucose / Q000378:metabolism; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008763:Methylhydrazines / Q000627:therapeutic use*; D032383:Myocytes, Cardiac / Q000378:metabolism; D010084:Oxidation-Reduction; D010879:Piperazines / Q000627:therapeutic use*; D000069458:Ranolazine; D051381:Rats; D017208:Rats, Wistar; D012519:Sarcoplasmic Reticulum / Q000378:metabolism; D014292:Trimetazidine / Q000627:therapeutic use*; D015854:Up-Regulation; D014665:Vasodilator Agents / Q000627:therapeutic use*
D000083:Acetanilides; D002317:Cardiovascular Agents; D004791:Enzyme Inhibitors; D004852:Epoxy Compounds; D005227:Fatty Acids; D007004:Hypoglycemic Agents; D008763:Methylhydrazines; D010879:Piperazines; D014665:Vasodilator Agents; C050147:3-(2,2,2-trimethylhydrazine)propionate; D000069458:Ranolazine; D005947:Glucose; C054207:etomoxir; D014292:Trimetazidine; D002118:Calcium